News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BTG, Inc. (BTGI) Strengthens Non-Invasive Prenatal Diagnostic Technology Patent Portfolio; Novel cell Differentiation Technique Brings Prenatal Testing From Maternal Blood Closer To Reality



10/19/2005 5:11:18 PM

BTG (LSE: BGC), the intellectual property and technology commercialization company, announced today that it has strengthened its non-invasive prenatal diagnosis patent portfolio through the acquisition of a novel cellular fetal DNA diagnostic. The technology, developed by Professor Maj Hulten, has the ability to identify fetal DNA from the mixed cell population in the maternal bloodstream. This will allow fetal chromosomes to be investigated for several chromosome disorders, including Trisomy 21 (underlying cause of Down syndrome) from a maternal blood sample, without contamination by maternal chromosomes.

Read at BioSpace.com


comments powered by Disqus
BTG, Inc.
BTG plc
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES